Vermillion Terminates OVA1 Licensing Deal with Quest | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion said after the close of the market on Monday that it has sent Quest Diagnostics a notice of termination of their licensing deal covering the OVA1 and Vasclir diagnostic tests.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.